Skip to main content
Fig. 7 | Advances in Rheumatology

Fig. 7

From: Brazilian recommendations for the use of nonsteroidal anti-inflammatory drugs in patients with axial spondyloarthritis

Fig. 7

Incidence of adverse events per organic system in the comparison of traditional NSAIDs versus placebo in patients with ankylosing spondylitis: meta-analyses of five randomized clinical trials. Subtitle: (1) Naproxen 500 mg vs placebo. (2) Ximoprofen 30 mg vs placebo. (3) NSAIDs (meloxicam 15 mg, meloxicam 22.5 mg, or piroxicam) vs placebo. (4) Ketoprofen 200 mg vs placebo. (5) Naproxen 1000 mg vs placebo. (6) Naproxen 500 mg vs placebo. (7) NSAIDs (meloxicam 15 mg, meloxicam 22.5 mg, or piroxicam) vs placebo. (8) Ketoprofen 200 mg vs placebo. (9) Naproxen 1000 mg vs placebo. (10) Ketoprofen 200 mg vs placebo. (11) Naproxen 500 mg vs placebo. (12) NSAIDs (meloxicam 15 mg, meloxicam 22.5 mg or piroxicam) vs placebo. (13) Ketoprofen 200 mg vs placebo. (14) Naproxen 1000 mg vs placebo. (15) Naproxen 500 mg vs placebo. (16) NSAIDs (meloxicam 15 mg, meloxicam 22.5 mg or piroxicam) vs placebo. (17) Ketoprofen 200 mg vs placebo

Back to article page